HAEi News

First patient enrolled in COVID-19 clinical trial with Ruconest

2020-08-10T16:46:23+02:00August 10, 2020|HAEi News|

The first patient has been enrolled in a randomized, controlled, investigator-initiated clinical trial in up to 150 patients for the treatment with Ruconest (recombinant human C1 inhibitor) of patients with confirmed COVID-19 (SARS-CoV-2) infections hospitalised with related severe pneumonia at the University Hospital Basel in Basel, Switzerland. In April 2020, Pharming Group N.V. reported encouraging results [...]

Intellia expects IND for HAE drug in H2 of 2021

2020-08-06T15:19:29+02:00August 6, 2020|HAEi News|

From Intellia Therapeutics, Inc.’s presentation of the financial results for the second quarter of 2020: NTLA-2002 is a wholly owned, in vivo development candidate for the treatment of HAE. Building on Intellia’s modular lipid nanoparticle (LNP) delivery system, NTLA-2002 is designed to knock out the prekallikrein B1 (KLKB1) gene in the liver after a single [...]

BioCryst will launch its first oral HAE drug this year

2020-08-06T13:45:17+02:00August 6, 2020|HAEi News|

“We are currently in an exciting transformation from a company primarily focused on R&D to one that is about to launch its first oral drug to patients with HAE (ORLADEYO) this year. We expect to end the year with ORLADEYO approved in the U.S. and Japan”, says President and CEO Jon Stonehouse, BioCryst Pharmaceuticals, Inc., [...]

Firazyr included in clinical trials for COVID-19 cure

2020-08-05T18:14:03+02:00August 5, 2020|HAEi News|

Together with the COVID R&D Alliance partners AbbVie, Inc. and Amgen Inc., Takeda Pharmaceutical Co. Ltd. has enrolled the first patients in the I-SPY COVID Trial (Investigation of Serial Studies to Predict Your COVID Therapeutic Response with Biomarker Integration and Adaptive Learning) clinical trial. The trial will evaluate the efficacy of a chemokine dual-receptor antagonist, a PDE4 [...]

Final approval for generic version of Firazyr

2020-07-15T08:32:02+02:00July 15, 2020|HAEi News|

Cipla Limited has received final approval for its Abbreviated New Drug Application (ANDA) for Icatibant Injectable 30mg/3mL from the United States Food and Drug Administration (US FDA). Cipla’s Icatibant Injectable Pre-Filled Syringe 30mg/3mL is AP-rated generic version of Shire’s Firazyr. Icatibant injection is indicated for the treatment of acute attacks of HAE in adults 18 years [...]

America Recognizes Chronic Disease Day 2020

2020-07-15T12:23:37+02:00July 14, 2020|HAEi News|

State and city governments, national patient advocacy groups, and local communities across the United States of America came together on 10 July 2020 to recognize Chronic Disease Day and support the chronic and rare disease communities during a time of unprecedented challenges for individuals who are immunocompromised. Chronic diseases are responsible for seven of the top 10 [...]

True Partnership can Bring the Best to Patient Care

2020-07-09T12:02:31+02:00July 9, 2020|HAEi News|

Late 2019, HAE International and the non-profit organization of leading clinical and research facilities in the field of allergy and asthma GA2LEN established GA2LEN/HAEi Angioedema Centers of Reference and Excellence – or in short ACARE. The joint venture with GA2LEN fulfills HAE International’s longstanding goal of establishing a worldwide network of accredited angioedema care centers. [...]

Updates from the HAEi Youngsters’ Community

2020-07-09T12:02:31+02:00July 9, 2020|HAEi News|

It has been almost two and a half years since the idea of the HAEi Youngsters Community was officially launched at the 2018 HAE Global Conference in Vienna, Austria. However, young HAE patients have been connecting online and staying in touch long before that. “At HAE International we are happy to be able to support [...]

Emergency Card now in 34 languages

2020-07-09T12:02:31+02:00July 9, 2020|HAEi News|

No matter if your preferred language is Arabic, Chinese, Greek, Latvian or Spanish there is an Emergency Card from HAE International for you. “As a matter of fact, we are presently at 34 languages and thereby covering a large portion of the globe”, says Henrik Balle Boysen, Executive Vice President & COO of HAE International: [...]